Bicine

Bicine

SCHEMBL1747701

N.O=C(O)CN(CCO)CCO

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.65
TSHR P16473 3/20 0.65
TDP1 Q9NUW8 2/20 0.65
KDM4E B2RXH2 2/20 0.65
BLM P54132 2/20 0.65
PMP22 Q01453 2/20 0.65
LMNA P02545 2/20 0.65
CYP2C19 P33261 2/20 0.65
CHRM2 P08172 1/20 0.65
ADRA2A P08913 1/20 0.65
DRD1 P21728 1/20 0.65
SLC6A2 P23975 1/20 0.65
SLC6A4 P31645 1/20 0.65
ADRA1A P35348 1/20 0.65
DRD3 P35462 1/20 0.65
SLC6A3 Q01959 1/20 0.65
HRH3 Q9Y5N1 1/20 0.65
EYA2 O00167 1/20 0.60
APP P05067 1/20 0.60
ACE P12821 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicine SCHEMBL34161 0.97 ALOX15 (0.68) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL177696 0.97 ALOX15 (0.68) ALOX15TSHRTDP1KDM4EBLM
Ammonia Solution, Strong SCHEMBL15643061 0.95 ALOX15 (0.75) ALOX15TSHRTDP1KDM4EBLM
Edetic Acid SCHEMBL9325471 0.95 ALOX15 (0.75) ALOX15TSHRTDP1KDM4EBLM
Ammonia Solution, Strong SCHEMBL9749925 0.95 ALOX15 (0.75) ALOX15TSHRTDP1KDM4EBLM
Ammonia Solution, Strong SCHEMBL2281626 0.95 ALOX15 (0.75) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL20471950 0.94 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL5883443 0.94 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL3357098 0.94 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
SCHEMBL8968107 0.94 TDP1 (0.74) ALOX15TSHRTDP1KDM4EBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534334-B1 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS BELROSE PHARMA INC (US) 2014-06-25 EP disclosed
EP-2338513-A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers ENZON, INC. (US) 2011-06-29 EP disclosed
US-7897647-B2 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro ENZON PHARMACEUTICALS, INC. (US) 2011-03-01 US disclosed
US-7597437-B2 Ink jet ink composition, ink set and ink jet treatment liquid, and ink jet recording method and ink jet recording apparatus using the same FUJI XEROX CO., LTD. (JP) 2009-10-06 US disclosed
EP-1534334-A4 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS ENZON INC (US) 2008-04-16 EP disclosed
EP-1628687-A4 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS ENZON INC (US) 2008-04-09 EP disclosed
US-20070166276-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers ENZON PHARMACEUTICALS, INC. 2007-07-19 US disclosed
US-20070109380-A1 Ink jet ink composition, ink set and ink jet treatment liquid, and ink jet recording method and ink jet recording apparatus using the same FUJI XEROX CO., LTD. (JP) 2007-05-17 US disclosed
US-20060286065-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers BELROSE PHARMA INC. 2006-12-21 US disclosed
US-7122189-B2 Releasable polymeric conjugates based on aliphatic biodegradable linkers ENZON, INC. (US) 2006-10-17 US disclosed
US-7087229-B2 Releasable polymeric conjugates based on aliphatic biodegradable linkers ENZON PHARMACEUTICALS, INC. (US) 2006-08-08 US disclosed
EP-1628687-A2 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS ENZON, INC. (US) 2006-03-01 EP disclosed
EP-1534334-A1 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS ENZON, INC. (US) 2005-06-01 EP disclosed
US-20050003448-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers BELROSE PHARMA INC. 2005-01-06 US disclosed
WO-2004108070-A2 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS ENZON, INC. (US) 2004-12-16 WO disclosed
US-20040241348-A1 Recording paper, and image recording method and device using the same FUJI XEROX CO., LTD. (JP) 2004-12-02 US disclosed
US-20040207701-A1 Ink jet ink composition, ink set and ink jet treatment liquid, and ink jet recording method and ink jet recording apparatus using the same FUJI XEROX CO., LTD. (JP) 2004-10-21 US disclosed
US-20040037802-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers BELROSE PHARMA INC. 2004-02-26 US disclosed
WO-2004014424-A1 RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS ENZON, INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050003448-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers CD44, PAICS, PCBP1 ALOX15 1113/4885TSHR 4144/4885TDP1 1229/4885
US-20040037802-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers CD44, PAICS, PCBP1 ALOX15 924/4885TSHR 4112/4885TDP1 955/4885
US-20070166276-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers CD44, PAICS, ALG1 ALOX15 391/4885TSHR 4153/4885TDP1 1404/4885
US-20060286065-A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers CD44, PAICS, PCBP1 ALOX15 1315/4885TSHR 3944/4885TDP1 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.